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Abstract: Several studies have suggested that
pentoxifylline, a theophylline-related drug
that decreases erytrhocyte stiffness, may be
useful in treatment of ischaemia reperfusion
injuries of brain, liver and small intestine in
animal experiments. Fourteen Wistar-Albino
rats weighing between 180-250 g were used
for the experiment and divided equally to two
groups.
Before
the
injury,
electroneuromyographic (ENMG) data were
recorded from right and left sciatic nerves.
Right sciatic nerves of the seven rats of group
1 were crushed with a clip. Same lesions were
performed on seven rats of group 2 and also
pentoxifylline (50mg/kg/day) was applied
intraperitoneally once in a day for 21 days.
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Immediately after the third week of the
operation, electrophysiological studies were

performed in the both groups again. In the
treated group latencies of compound muscle
action potentials (CMAP) treated with the
pentoxifylline were found shorter than the
untreated group, but this difference was not
statistically significant. Whereas, in the
animals
treated
with
pentoxifylline,
amplitudes of the CMAP recordings were
higher than the untreated group and the
difference was statistically significant.
These results suggested that pentoxifylline
has a positive effect on axon regeneration but
no significant improving effect on segmental
remyelination.
Key Words: Experimental nerve injury,
pentoxifylline, sciatic nerve

Introduction

Materials and Methods

Peripheral nerve injury was always been a critical
clinical problem in human history, for this reason a
variety of experimental and clinical studies has conducted
by the researchers to seek new treatment methods of
these lesions. Complete lesions, such as neurotmesis can
be treated by surgical methods but axonotmetic nerve
injury is treatable with conservative medical treatment
methods. Studies in the field of peripheral nerve injury
were began in 1795 and especially accelerated during the
World War I and II on account of war injuries. Today,
pharmacological agents are used in the treatment of these
lesions, including non-steroid anti-inflammatory agents,
steroids (1), nerve growth factors (2,3), Rheomacrodex
(4), thyroid hormones (5), growth hormone (6), ACTH
(3,7) and insulin-like-peptide (6,8).

This study had been conducted in the Institute of
Experimental Surgery of Karadeniz Technical University
in 1998. Fourteen Wistar-Albino rats were used and
divided into equal two groups regardless of sex, seven in
control group and seven in the treated with
pentoxifylline, the weights of animals were between 180
and 270 grams.

In this study, we used pentoxifylline, a
phosphodiesterase inhibitor, for its rheologic properties
and discussed its effects on the nerve injury model,
electrophysiologically.

Animals were anesthetized with 70-mg/kg ketamineHCl and positioned on wooden frame, designed for
experimental studies. Before injuries were performed
ENMG recordings were taken in all groups. Then the right
sciatic nerves of the animals were explored under a
surgical microscope. Then, sciatic nerve was clipped by
mini aneurism clip, (Yasargil FE693 Aneurism Clip,
Aesculap) for 90 seconds to form crush injury and then
removed. In all animals, post injury ENMG recordings
were performed.
Fifty-mgr/kg/day pentoxifylline (Trental, Hoechst)
was given intraperitoneally to all experimental groups in
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the first day of the injury, once a day, and repeated for in
every twenty-four hours for twenty-one days. After the
twenty-four hours from the last drug application, ENMG
recordings of all animals were taken again and evaluated.

Table 1. ENMG Results.
On the third week evaluation

Electrophysiological Evaluation Method
Electrophysiological recordings were performed in a
quiet room with an ambient temperature between 22-23
ºC, using Medelec Premier ENMG apparatus. Wraparound
ground electrode (54482T) placed on the animal’s thorax
externally. Modified surface electrodes (Medronic,
9013L0202, 4 mm in diamater) were used to record
CMAPs. The hind limbs of the rats shaved accordingly.
Using electrode gel, the cathode was located on tibialis
anterior muscle, 1.5 cm distal to injury zone, and the
reference electrode located on the tendon of the muscle.
Adjusting distance between cathode and anode to 1 cm,
the sciatic nerve was stimulated at the sciatic notch 1.5
cm proximal to injury zone, by two monopolar needle
electrodes. Supra-maximal pulses, 0.05 ms in duration,
were delivered. Filter settings were 0.1-3 KHz; sweep
speed 2 ms/div, and sensitivity 2-10mV/div. The latency
was measured to the onset of the CMAP, thus giving a
measure of the conduction velocity of the fastest fiber.
Baseline to peak amplitudes, which show the numbers of
fibers activated by nerve stimulation, were also
measured.
Electrophysiological data’s were analyzed using MannWhitney U test

Results
ENMG Findings:
The latencies of the CMAP recordings of the treated
animals were shorter than the untreated group, but this
difference was not statistically significant (p>0.05).
Whereas, in the animals treated with pentoxifylline,
Amplitudes of CMAPs were higher than the untreated
group and the difference was statistically significant
(p<0.01) as ENMG findings were summarized in table 1.

Discussion
Pentoxifylline is a phosphodiesterase inhibitor with
rheologic properties along with the effects of decreasing
the viscosity of the blood. Due to it’s phosphodiesterase
inhibition effect, cyclic adenosine monophosphate (cAMP)
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Latency (ms)
Amplitude (mV)

Preinjury
n=14

Injured
n=7

Injured +treated
n=7

1.16±0.15
16.35±2.87

2.07±0.52
2.35±1.73

1.84±0.48
6.12±0.52*

* = On the third week evaluation mean amplitude of CMAPs were
significantly higher in pentoxifylline treated group versus untreated
group.

levels increase in erythrocytes, endothelium, and
surrounding tissues (9). In addition to this rheologic
effects of pentoxifylline, it has also immunomodulatory
properties which produces vascular endothelial
stabilization and autoimmune inhibition, especially
significant in the treatment of neuritis (10). It has also
been used in clinical and experimental studies of Bell’s
palsy (4,11,12), carpal tunnel syndrome (13), optic
nerve’s circulatory disorders (14), cerebrovascular
accidents and some microvascular disorders (15, 16, 17,
18).
Functional integrity of peripheral nerves primarily
depends on the sufficient blood supply like other tissues.
Acute ischemic lesions of the peripheral nerves can be
reversible but severe and prolonged ischemic process of
the nerves can lead to extensive axon injury along with
Wallerian degeneration (19). The severity of these lesions
depends on the duration and the intensity of ischaemia
and compression. Vasa nervorum can also be affected by
trauma, diabetes and by some metabolites. These factors
can lead to ischemic neuropathy (20,21,22) and
reperfusion injury during peripheral nerve injury (23).
Ischaemia leads an insufficient ATP supply when ATP
consumption in all damaged tissues increase. Anaerobic
metabolic process levels increase in such process and
eventually hypoxanthine levels also increase in ischemic
tissues. In the reperfusion phase of ischaemia superoxide
radical levels and hydrogen peroxide levels increase.
These can lead to the damage of the tissues (18 ).
Pentoxifylline had been used in some experimental
and clinical studies especially to restore the normal
function of the vasa vasorum (22,24). Although
pentoxifylline has no effect on vascular tonus, it
contributes the amolioration of the microcirculation
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Mean latency values in groups. Latency were significantly
shorter in preinjury group, but there were no significant
differences between injured and injured+untreated groups.

regulation and intovascular cell dynamics (5,18). Studies
showed that pentoxifylline decreases peripheral nerve
injury with preventing free radical production by
neutrophil inhibitory effect, and also decreasing the levels
of cytokines, malondialdehyde and myeloperoxidase (18).
Pentoxifylline is also known to increase whole blood
filtration rate, and recent evidences suggests that
pentoxifylline increases the filtration rate of
polymorphonuclear leucocytes in the tissues (25). Also
deformability of neutrophils increased when they treated
with pentoxifylline. These results have been consistent
with the hypothesis of the beneficial effect of
pentoxifylline on microvascular perfusion is partly due to
an inhibition of polymorphonuclear cell stiffness and
activation (25).
Aim of this study was testing of these beneficial
effects of pentoxifylline in the peripheral crush injury
which causes axon degeneration, myelin destruction and
myelin destruction with nerve ischemia (26). In the
evaluation of peripheral nerve regeneration, ENMG
recordings revealed important information in the studies
of crush injury. ENMG recordings are very important in
this issue because it confirms evidences of regeneration
weeks or months before motor functions improvements
can be observed. Latency and amplitude of CMAP are the

Figure 2.

Mean CMAP amplitudes in groups. Amplitudes were
significantly higher in preinjury group and there were
significant differences between injured and injured+treated
groups.

principle criterion has to be evaluated. Amplitude is
directly correlated with active neuron number and latency
is a reliable indicator of demyelination after the injury
(27).
Previous studies proved that intraperitoneal
pentoxifylline treatment for three weeks is adequate to
evaluate its effects by ENMG (28,29). Pre and post injury
evaluations by both histological and ENMG findings
demonstrated that the lesion produced by the clipcompression was in grade II and III, according to of
Sunderland’s classification (30).
In our study, we found a statistically significant
difference for amplitudes between injured and injured +
treated groups. This difference demonstrates that axon
regeneration was augmented by pentoxifylline treatment.
There was no statistically significant difference for
latency. This result demonstrates that pentoxifylline has
no significant improving effect on segmental
remyelination.
Correspondence author:
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